Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | PLK4 | O00444 | 1/20 | 0.37 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.37 |
| ▸ | AURKA | O14965 | 1/20 | 0.37 |
| ▸ | CHUK | O15111 | 1/20 | 0.37 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.37 |
| ▸ | PAK4 | O96013 | 1/20 | 0.37 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.37 |
| ▸ | CDK1 | P06493 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7859358 | 1.00 | ALDH1A1 (0.46) | ALDH1A1MAPTKDM4EMEN1NPC1 | |
| SCHEMBL17234569 | 1.00 | ALDH1A1 (0.46) | ALDH1A1MAPTKDM4EMEN1NPC1 | |
| Hydrochloric Acid SCHEMBL7526024 | 0.98 | ALDH1A1 (0.44) | ALDH1A1MAPTKDM4EMEN1NPC1 | |
| Hydrochloric Acid SCHEMBL7526029 | 0.98 | ALDH1A1 (0.44) | ALDH1A1MAPTKDM4EMEN1NPC1 | |
| SCHEMBL27111321 | 0.83 | PLK4 (0.35) | PLK4CHEK1AURKACHUKDAPK3 | |
| SCHEMBL1770184 | 0.83 | PLK4 (0.35) | PLK4CHEK1AURKACHUKDAPK3 | |
| SCHEMBL23907305 | 0.81 | ALDH1A1 (0.48) | ALDH1A1MAPTKDM4EMEN1NPC1 | |
| SCHEMBL2173551 | 0.81 | ALDH1A1 (0.48) | ALDH1A1MAPTKDM4EMEN1NPC1 | |
| SCHEMBL2173552 | 0.81 | ALDH1A1 (0.48) | ALDH1A1MAPTKDM4EMEN1NPC1 | |
| SCHEMBL2024987 | 0.77 | ALDH1A1 (0.46) | ALDH1A1MAPTKDM4EMEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1576093-A4 | 3-DEOXYGLUCOSONE AND SKIN | DYNAMIS THERAPEUTICS INC (US) | 2009-07-08 | — | — | EP | claimed |
| CN-101084235-A | 3-deoxyglucosone and skin | DYNAMIS THERAPEUTICS INC (US) | 2007-12-05 | — | — | CN | claimed |
| US-20070065443-A1 | Fructoseamine 3 kinase and the formation of collagen and elastin | DYNAMIS THERAPEUTICS, INC. | 2007-03-22 | — | — | US | claimed |
| EP-1753861-A2 | FRUCTOSEAMINE 3 KINASE AND THE FORMATION OF COLLAGEN AND ELASTIN | Dynamis Therapeutics, Inc. (US) | 2007-02-21 | — | — | EP | claimed |
| EP-1576093-A2 | 3-DEOXYGLUCOSONE AND SKIN | Dynamis Therapeutics, Inc. (US) | 2005-09-21 | — | — | EP | claimed |
| WO-2005079463-A2 | FRUCTOSEAMINE 3 KINASE AND THE FORMATION OF COLLAGEN AND ELASTIN | DYNAMIS THERAPEUTICS, INC. (US) | 2005-09-01 | — | — | WO | claimed |
| US-20050159383-A1 | Administering enzyme inhibitors; wrinkling and aging resistance; prevents formation Advanced Glycation End Products (AGEs) | DYNAMIS THERAPEUTICS, INC. | 2005-07-21 | — | — | US | claimed |
| US-20030219440-A1 | 3-deoxyglucosone and skin | DYNAMIS THERAPEUTICS, INC. | 2003-11-27 | — | — | US | claimed |
| WO-2003089601-A2 | 3-DEOXYGLUCOSONE AND SKIN | DYNAMIS THERAPEUTICS, INC. (US) | 2003-10-30 | — | — | WO | claimed |
| CN-1377642-A | Use of compound for preparing medicine for curing and preventing non-insulin dependent diabetes or obesity | BIOVITRUM AB (SE) | 2002-11-06 | — | — | CN | claimed |
| EP-0793646-B1 | AMINOGUANIDINE CARBOXYLATES FOR THE TREATMENT OF NON-INSULIN-DEPENDENT DIABETES MELLITUS | UPJOHN CO (US) | 2001-09-05 | — | — | EP | claimed |
| CN-1164226-A | Aminoguanidine carboxylates for the treatment of non-insulin dependent diabetes mellitus | UPJOHN CO (US) | 1997-11-05 | — | — | CN | claimed |
| US-20240180912-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CREATINE TRANSPORT AS A TREATMENT FOR CANCER | INSPIRNA, INC. (US) | 2024-06-06 | — | — | US | disclosed |
| EP-3950673-A1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | Inspirna, Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
| EP-3137447-B1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | RGENIX INC (US) | 2021-06-30 | — | — | EP | disclosed |
| US-10717704-B2 | Inhibitors of creatine transport and uses thereof | RGENIX, INC. (US) | 2020-07-21 | — | — | US | disclosed |
| US-5272165-A | 2-alkylidene-aminoguanidines and methods of use therefor | THE ROCKEFELLER UNIVERSITY (US) | 1993-12-21 | — | — | US | disclosed |
| US-5243071-A | Acetoacetic acid guanyl hydrazone; inhibits food spoilage and protein aging | THE ROCKEFELLER UNIVERSITY (US) | 1993-09-07 | — | — | US | disclosed |
| WO-1992019236-A1 | 2-ALKYLIDENE-AMINOGUANIDINES FOR INHIBITING ADVANCED NONENZYMATICGLYCOSYLATION OF PROTEINS | THE ROCKEFELLER UNIVERSITY (US) | 1992-11-12 | — | — | WO | disclosed |
| US-5130324-A | For inhibiting nonezymatic crosslinking of glycosylation products of proteins | THE ROCKEFELLER UNIVERSITY (US) | 1992-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070065443-A1 | Fructoseamine 3 kinase and the formation of collagen and elastin | FN3K, PDXK, COLGALT1 | ALDH1A1 927/4885MAPT 677/4885KDM4E 1956/4885 |
| US-20240180912-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CREATINE TRANSPORT AS A TREATMENT FOR CANCER | KRAS, FOLR2, SLC19A1 | ALDH1A1 1159/4885MAPT 2868/4885KDM4E 3385/4885 |
| US-10717704-B2 | Inhibitors of creatine transport and uses thereof | CKMT1A; CKMT1B, SLC25A1, SLC2A1 | ALDH1A1 2023/4885MAPT 3113/4885KDM4E 1519/4885 |
| US-20030219440-A1 | 3-deoxyglucosone and skin | DPM1, G6PD, UGGT1 | ALDH1A1 383/4885MAPT 3453/4885KDM4E 897/4885 |
| US-20050159383-A1 | Administering enzyme inhibitors; wrinkling and aging resistance; prevents formation Advanced Glycation End Products (AGEs) | AGER, GLA, GALE | ALDH1A1 357/4885MAPT 2715/4885KDM4E 441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.